Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

A multicomponent intervention to prevent delirium in hospitalized older patients. (1/2588)

BACKGROUND: Since in hospitalized older patients delirium is associated with poor outcomes, we evaluated the effectiveness of a multicomponent strategy for the prevention of delirium. METHODS: We studied 852 patients 70 years of age or older who had been admitted to the general-medicine service at a teaching hospital. Patients from one intervention unit and two usual-care units were enrolled by means of a prospective matching strategy. The intervention consisted of standardized protocols for the management of six risk factors for delirium: cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration. Delirium, the primary outcome, was assessed daily until discharge. RESULTS: Delirium developed in 9.9 percent of the intervention group as compared with 15.0 percent of the usual-care group, (matched odds ratio, 0.60; 95 percent confidence interval, 0.39 to 0.92). The total number of days with delirium (105 vs. 161, P=0.02) and the total number of episodes (62 vs. 90, P=0.03) were significantly lower in the intervention group. However, the severity of delirium and recurrence rates were not significantly different. The overall rate of adherence to the intervention was 87 percent, and the total number of targeted risk factors per patient was significantly reduced. Intervention was associated with significant improvement in the degree of cognitive impairment among patients with cognitive impairment at admission and a reduction in the rate of use of sleep medications among all patients. Among the other risk factors per patient there were trends toward improvement in immobility, visual impairment, and hearing impairment. CONCLUSIONS: The risk-factor intervention strategy that we studied resulted in significant reductions in the number and duration of episodes of delirium in hospitalized older patients. The intervention had no significant effect on the severity of delirium or on recurrence rates; this finding suggests that primary prevention of delirium is probably the most effective treatment strategy.  (+info)

Can we cure indolent lymphomas? (2/2588)

The current consensus is that indolent lymphomas are incurable disorders. There are some indications that these malignancies are potentially curable. Indeed, not all indolent lymphomas are currently incurable. For example, patients with Ann Arbor stage I-II indolent lymphomas can experience long-term disease-free survival and probable cure. Also, from the available literature data, it seems that the achievement of a molecular complete remission is a desirable objective. Patients who achieve a persistently negative PCR state seldom relapse, whereas the opposite is true for persistently positive cases. In view of its excellent correlation with disease-free survival when examined serially in multiple blood or marrow samples, the PCR technique has the potential of providing a tumor marker that can be used as an early end point for clinical trials. By serving as an early surrogate end point, PCR could play an important role in expediting the development of new treatment strategies. Whether IFN is capable of increasing the molecular complete remission rate as measured by PCR is not known. However, it is clear that from the clinical standpoint, IFN has been able to increase 2-fold the length of remission in patients with advanced indolent lymphomas. In at least two studies, this has been associated with prolongation of survival. More intensive regimens such as alternating triple therapy, when used in combination with IFN, seem to have improved the quality of remissions as judged by the PCR assay. Finally, the site where the bcl-2 breakpoint occurs seems to have clinical significance. Those follicular lymphomas with germ-line bcl-2, in our experience, have behaved more aggressively than the others, and their failure-free survival seems different from the usual indolent lymphomas and more closely resembles the large cell lymphomas. Although the biological significance of this observation is not yet understood, this group might actually constitute a prognostically different subset with a more aggressive and perhaps more curable lymphoma. Whether the plateau observed in their failure-free survival curve will be maintained with more follow-up and whether they might be a curable subset remain to be determined.  (+info)

Low-molecular-weight heparin in outpatient treatment of DVT. (3/2588)

Patients with a diagnosis of acute deep venous thrombosis have traditionally been hospitalized and treated with unfractionated heparin followed by oral anticoagulation therapy. Several clinical trials have shown that low-molecular-weight heparin is at least as safe and effective as unfractionated heparin in the treatment of uncomplicated deep venous thrombosis. The use of low-molecular-weight heparin in an outpatient program for the management of deep venous thrombosis provides a treatment alternative to hospitalization in selected patients. Use of low-molecular-weight heparin on an outpatient basis requires coordination of care, laboratory monitoring, and patient education and participation in treatment. Overlapping the initiation of warfarin permits long-term anticoagulation. Advantages include a decreased incidence of heparin-induced thrombocytopenia and fewer episodes of bleeding complications. Future clinical trials evaluating the safety and efficacy of low-molecular-weight heparin in the treatment of complicated deep venous thrombosis will further define appropriate indications for use and strategies for outpatient management.  (+info)

Time course of respiratory decompensation in chronic obstructive pulmonary disease: a prospective, double-blind study of peak flow changes prior to emergency department visits. (4/2588)

The aim of this study was to look at changes in peak expiratory flow rates (PEFR) prior to emergency department visits for decompensated chronic obstructive pulmonary disease (COPD). It was designed as a prospective, double-blind study at the Albuquerque Veterans Affairs Medical Center. Twelve patients with an irreversible component of airflow obstruction on pulmonary function tests were assessed. At entry, all subjects were instructed in the use of a mini-Wright peak flow meter with electronic data storage. They then entered a 6-month monitoring phase in which they recorded PEFR twice daily, before and after bronchodilators. The meter displays were disabled so that the patients and their physicians were blinded to all values. Medical care was provided in the customary manner. Patients were considered to have respiratory decompensation if they required treatment for airflow obstruction in the Emergency Department (ED) and no other causes of dyspnea could be identified. Simple linear regression was used to model changes in PEFR over time. The 12 subjects had 22 episodes of respiratory decompensation during 1741 patient-days of observation. Two episodes could not be analysed because of missing values. Ten episodes in seven subjects were characterized by a significant linear decline in at least one peak flow parameter prior to presentation. The mean rates of change for the four daily parameters varied from 0.22% to 0.27% predicted per day (or 1.19 to 1.44 1 min-1 day-1). The average decrement in these parameters ranged from 30.0 to 33.8 1 min-1 (or 18.6%-25.9% of their baseline values). No temporal trends were found for the 10 episodes occurring in the other five subjects. We concluded that respiratory decompensation is characterized by a gradual decline in PEFR in about half of cases. Future studies should be done to elucidate the mechanisms of respiratory distress in the other cases.  (+info)

Enhancing the identification of excessive drinkers on medical wards: a 1-year follow-up study. (5/2588)

This paper describes a 1-year follow-up study examining whether hospital ward doctors and nurses continue to take quantitative alcohol histories and provide brief intervention to problem drinkers on general medical wards after the introduction of a simple protocol. Regular training in the use of this protocol was stipulated in the annual service contract between the Health Authority and the Hospital Trusts. Improvements in staff practice persisted at 1-year follow-up, although it fell from a peak at an earlier phase of the study. The positive role of state purchasers of health services in sustaining improvements in clinical practice is discussed.  (+info)

Agreeing criteria for audit of the management of induced abortion: an approach by national consensus survey. (6/2588)

OBJECTIVE: To obtain a national consensus view of suggested criteria for good quality care in induced abortion to serve as a basis for standards for audit to assess current clinical practice. DESIGN: Postal, questionnaire survey assessing consensus agreement with criteria identified from a literature review and refined by an invited panel of four gynaecologists and the gynaecology audit project in Scotland (GAPS) committee. SETTING: Scotland. SUBJECTS: All 132 practising consultant gynaecologists. MAIN MEASURES: Overall level of agreement with each of 20 suggested audit criteria. RESULTS: 121 completed questionnaires were received (response rate 92%), of which 119 were returned in time for analysis; 107 came from consultants who practised abortion routinely and were included in the analysis. Nineteen of 20 suggested criteria were validated by an overall balance of agreement. The most strongly supported criterion (agreement score +93) was for ascertaining rhesus status of the woman and prophylaxis after abortion, if indicated. The only criterion to elicit a negative agreement score (-27) was that dilatation and evacuation is the best method of abortion at 12-15 weeks' gestation. The ranked and prioritised criteria resulting from this exercise are being used within a national audit project. CONCLUSIONS: A postal questionnaire survey among interested clinicians resulted in a good response rate and enabled the audit criteria to be validated and ranked more objectively and among more clinicians, than would have been possible by group discussion.  (+info)

Audit of thrombolysis initiated in an accident and emergency department. (7/2588)

Early thrombolytic therapy after acute myocardial infarction is important in reducing mortality. To evaluate a system for reducing in-hospital delays to thrombolysis pain to needle and door to needle times to thrombolysis were audited in a major accident and emergency (A and E) department of a district general hospital and its coronary care unit (CCU), situated about 5 km away. Baseline performance over six months was assessed retrospectively from notes of 43 consecutive patients (group 1) transferred to the CCU before receiving thrombolysis. Subsequently, selected patients (23) were allowed to receive thrombolysis in the A and E department before transfer to the CCU. The agent was administered by medical staff in the department after receiving oral confirmation of myocardial infarction from the admitting medical officer in the CCU on receipt of fax transmission of the electrocardiogram. A second prospective audit during six months from the start of the new procedure established time intervals in 23 patients eligible to receive thrombolysis in the A and E department (group 2b) and 30 ineligible patients who received thrombolysis in the CCU (group 2a). The groups did not differ significantly in case mix, pre-hospital delay, or transfer time to the CCU. In group 2b door to needle time and pain to needle time were reduced significantly (geometric mean 38 min v 121 min (group 2a) and 128 min (group 1); 141 min v 237 min (group 2a) and 242 min (group 1) respectively, both p < 0.0001). The incidence of adverse effects was not significantly different. Nine deaths occurred (six in group 1, three in group 2b), an in-hospital mortality of 9.9%. Thrombolysis can be safely instituted in the A and E department in selected patients, significantly reducing delay to treatment.  (+info)

Improving quality through cost recovery in Niger. (8/2588)

New evidence on the quality of health care from public services in Niger is discussed in terms of the relationships between quality, costs, cost-effectiveness and financing. Although structural attributes of quality appeared to improve with the pilot project in Niger, significant gaps in the implementation of diagnostic and treatment protocols were observed, particularly in monitoring vital signs, diagnostic examination and provider-patient communications. Quality improvements required significant investments in both fixed and variable costs; however, many of these costs were basic input requirements for operation. It is likely that optimal cost-effectiveness of services was not achieved because of the noted deficiencies in quality. In the test district of Boboye, the revenues from the copayments alone covered about 34% of the costs of medicines or about 20% of costs of drugs and administration. In Say, user fees covered about 50-55% of the costs of medicines or 35-40% of the amount spent on medicines and cost-recovery administration. In Boboye, taxes plus the additional copayments covered 120-180% of the cost of medicines, or 75-105% of the cost of medicines plus administration of cost recovery. Decentralized management and legal conditions in the pilot districts appeared to provide the necessary structure to ensure that the revenues and taxes collected would be channelled to pay for quality improvements.  (+info)

Clinical protocols, also known as clinical practice guidelines or care paths, are systematically developed statements that assist healthcare professionals and patients in making decisions about the appropriate healthcare for specific clinical circumstances. They are based on a thorough evaluation of the available scientific evidence and consist of a set of recommendations that are designed to optimize patient outcomes, improve the quality of care, and reduce unnecessary variations in practice. Clinical protocols may cover a wide range of topics, including diagnosis, treatment, follow-up, and disease prevention, and are developed by professional organizations, government agencies, and other groups with expertise in the relevant field.

Genetic therapy, also known as gene therapy, is a medical intervention that involves the use of genetic material, such as DNA or RNA, to treat or prevent diseases. It works by introducing functional genes into cells to replace missing or faulty ones caused by genetic disorders or mutations. The introduced gene is incorporated into the recipient's genome, allowing for the production of a therapeutic protein that can help manage the disease symptoms or even cure the condition.

There are several approaches to genetic therapy, including:

1. Replacing a faulty gene with a healthy one
2. Inactivating or "silencing" a dysfunctional gene causing a disease
3. Introducing a new gene into the body to help fight off a disease, such as cancer

Genetic therapy holds great promise for treating various genetic disorders, including cystic fibrosis, muscular dystrophy, hemophilia, and certain types of cancer. However, it is still an evolving field with many challenges, such as efficient gene delivery, potential immune responses, and ensuring the safety and long-term effectiveness of the therapy.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Reproducibility of results in a medical context refers to the ability to obtain consistent and comparable findings when a particular experiment or study is repeated, either by the same researcher or by different researchers, following the same experimental protocol. It is an essential principle in scientific research that helps to ensure the validity and reliability of research findings.

In medical research, reproducibility of results is crucial for establishing the effectiveness and safety of new treatments, interventions, or diagnostic tools. It involves conducting well-designed studies with adequate sample sizes, appropriate statistical analyses, and transparent reporting of methods and findings to allow other researchers to replicate the study and confirm or refute the results.

The lack of reproducibility in medical research has become a significant concern in recent years, as several high-profile studies have failed to produce consistent findings when replicated by other researchers. This has led to increased scrutiny of research practices and a call for greater transparency, rigor, and standardization in the conduct and reporting of medical research.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

"Clinical packages & Protocols". katetchanturia.com. "Academy of Europe: Tchanturia Kate". www.ae-info.org. Retrieved 28 ... Pathway for Eating disorders and Autism developed from Clinical Experience). This clinical pathway was funded by The Health ... She has developed a novel clinical pathway for patients with comorbid autism and eating disorders at the South London and ... After relocating to London in 1997, she became a clinical research fellow at the Institute of Psychiatry, King's College London ...
"Clinical protocol. Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene (ASPA) to ...
Limited clinical protocols for patient management. Limited technical operational manuals for program implementation. Health ...
... in Clinical Practice Using SEE-Fim Protocol". JNCI Cancer Spectrum. 2 (4): pky061. doi:10.1093/jncics/pky061. ISSN 2515-5091. ... The SEE-FIM protocol is a pathology dissection protocol for Sectioning and Extensively Examining the Fimbria (SEE-FIM). This ... The SEE-FIM protocol consists of five steps (See Figure): The tube is fixed for at least 2 hours in laboratory fixative. The ... The protocol is used to exclude occult cancer. A recent study of over 25,000 women who underwent this procedure reported no ...
In a clinical trial, the protocol is carefully designed to safeguard the health of the participants as well as answer specific ... While in a clinical trial, participants following a protocol are seen regularly by research staff to monitor their health and ... A good clinical protocol ensures that blinding is as effective as possible within ethical and practical constrains. During the ... In fact, such predefined protocols are an essential component of Good Laboratory Practice (GLP) and Good Clinical Practice (GCP ...
Perlman, Sally E.; Nakajyma, Steven T.; Hertweck, S. Paige (2004). Clinical protocols in pediatric and adolescent gynecology. ... Perlman, Sally E.; Nakajyma, Steven T.; Hertweck, S. Paige (2004). Clinical protocols in pediatric and adolescent gynecology. ... Clinical and Pathological Aspects, Greenwich Medical Media: London, a)p.453, b)p.455 c)p.460. "Muslim women in France regain ...
Perlman, Sally E.; Nakajyma, Steven T.; Hertweck, S. Paige (2004). Clinical protocols in pediatric and adolescent gynecology. ... Clinical and Pathological Aspects, Greenwich Medical Media: London, a)p.453, b)p.455 c)p.460. The Marks of Childhood or the ... vaginal examinations for verifying a woman's virginity are a clinical practice which are at times state-enforced. These types ...
ISBN 978-0-7131-4452-9. Perlman SE, Nakajyma ST, Hertweck SP (2004). Clinical protocols in pediatric and adolescent gynecology ... Alldredge BK, Corelli RL, Ernst ME (2012). Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs. Lippincott ... Sirven JI, Malamut BL (2008). Clinical Neurology of the Older Adult. Lippincott Williams & Wilkins. pp. 230-232. ISBN 978-0- ... Balon R, Segraves RT (2009). Clinical Manual of Sexual Disorders. American Psychiatric Pub. p. 258. ISBN 978-1-58562-905-3. ...
Perlman, Sally E.; Nakajyma, Steven T.; Hertweck, S. Paige (2004). Clinical protocols in pediatric and adolescent gynecology. ... Clinical and Pathological Aspects, Greenwich Medical Media: London, a)p.453, b)p.455 c)p.460. ISBN 978-1-84-110026-5 Heger, ... Journal of Clinical Forensic Medicine. 13 (4): 172-180. doi:10.1016/j.jcfm.2006.02.006. ISSN 1353-1131. PMID 16564196. Hymen ...
In 2006, an invited group of clinicians met in Chicago and reviewed clinical evidence and protocols, and adopted a new term for ... Large majorities of respondents opposed standard clinical protocols. A 2016 follow-up to the 2006 Consensus Statement, termed a ... a US professor of Clinical Medical Humanities and Bioethics, argues that little has changed in actual clinical practice in ... The committee stated: "clinical intervention pathways stated to be based on probabilities of cancer risk may be encapsulating ...
In 2006, an invited group of clinicians met in Chicago and reviewed clinical evidence and protocols, argued that and adopted a ... Large majorities of respondents opposed standard clinical protocols. A 2016 follow-up to the 2006 Consensus Statement, termed a ... There are no controlled clinical trials of the efficacy of early (less than 12 months of age) versus late surgery (in ... Clinical Pediatric and Adolescent Endocrinology.. Philadelphia: Saunders. An example of a now-obsolete recommendation to ...
"What stops hospital clinical staff from following protocols? An analysis of the incidence and factors behind the failure of ... These tools can predict clinical deterioration based upon the patient's trait (e.g. has epilepsy) and detect deterioration ... UK National Institute for Health and Clinical Excellence (NICE) (July 2007). "Acutely ill patients in hospital: recognition of ... A rapid response system consists of two clinical components, an afferent component, an efferent component, and two ...
Clinical Applications of Capillary Electrophoresis: Methods and Protocols. Methods in Molecular Biology. Vol. 1972. New York, ...
Protocols in Clinical Embryology and ART. JP Medical Ltd. pp. 379-. ISBN 978-93-5025-765-4. Kuhl H (August 2005). "Pharmacology ...
Clinical trial protocols are the centerpiece of the IND. Detailed protocols for proposed clinical studies to assess whether the ... If the FDA detects a problem, it may place a clinical hold on the IND, prohibiting the start of the clinical studies until the ... Once an IND is submitted, the FDA has 30 days to object to the IND or it automatically becomes effective and clinical trials ... About half of the INDs fail in preclinical and clinical phases of drug development. The FDA runs a medical marijuana IND ...
Wyatt, Richard Jed; Chew, Robert H. (2008). Wyatt's Practical Psychiatric Practice: Forms and Protocols for Clinical Use. ... Shin, Jin; Park, Doo-Heum; Ryu, Seung-Ho; Ha, Jee Hyun; Kim, Seol Min; Jeon, Hong Jun (2020-07-24). "Clinical implications of ... Ch 1 in Barlow, D. H. (Ed) Clinical handbook of psychological disorders: A step-by-step treatment manual. New York: Guilford. ... The disappearance of residual and sub-clinical agoraphobic avoidance, and not simply of panic attacks, should be the aim of ...
Forms and Protocols for Clinical Use. American Psychiatric Pub. pp. 142-. ISBN 978-1-58562-687-8. Fortinash KM, Worret PA (13 ... Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate ... Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas. Janssen PA, ... The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50-9. PMID 6143748. Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA ...
Kellams A, Harrel C, Omage S, Gregory C, Rosen-Carole C (May 2017). "ABM Clinical Protocol #3: Supplementary Feedings in the ... Eglash A, Simon L (September 2017). "ABM Clinical Protocol #8: Human Milk Storage Information for Home Use for Full-Term ... Boies EG, Vaucher YE (December 2016). "ABM Clinical Protocol #10: Breastfeeding the Late Preterm (34-36 6/7 Weeks of Gestation ... Boies EG, Vaucher YE (December 2016). "ABM Clinical Protocol #10: Breastfeeding the Late Preterm (34-36 6/7 Weeks of Gestation ...
MOMENTUM 3 IDE Clinical Study Protocol (HM3). U.S. National Institutes of Health. ClinicalTrials.gov. Retrieved September 16, ... is still in clinical trials for destination therapy. In a two-year randomized controlled clinical trial published in 2009 ... It began undergoing clinical trials in the U.S. and internationally in mid 2014. In mid 2014, CE Mark trials also started for ... It is cleared for clinical use up to six hours, and can be used as a short-term solution to support the circulation while ...
AIDS Clinical Trials Protocol 5015 Team (2010). "Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor ... In the following year, he served as a Clinical Fellow in Infectious Diseases and Clinical Pharmacology at the Johns Hopkins ... results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. Clinical Infectious Diseases, 50, ... American Society for Clinical Pharmacology and Therapeutics 1995 - Pfizer Visiting Professor of Medicine and Clinical ...
Spinifex Pharmaceuticals Pty Limited (2011). "CLINICAL STUDY PROTOCOL: Protocol No. EMA401-003". {{cite journal}}: Cite journal ... Spinifex Pharmaceuticals Pty Limited (2011). "CLINICAL STUDY PROTOCOL: Protocol No. EMA401-003". {{cite journal}}: Cite journal ... Spinifex Pharmaceuticals Pty Limited (2011). "CLINICAL STUDY PROTOCOL: Protocol No. EMA401-003". {{cite journal}}: Cite journal ... Phase I clinical trial have indicated that doses of EMA401 up to 400 mg are safe in humans. Spinifex Pharmaceuticals reported ...
"Clinical Study Protocol mRNA-1273-P301" (PDF). Moderna. 20 August 2020. Archived from the original (PDF) on 17 September 2020. ... The clinical trial is ongoing and is set to conclude in late 2022. Pregnant and breastfeeding women were also excluded from the ... A review by the FDA in December 2020, of interim results of the phase III clinical trial on mRNA-1273 showed it to be safe and ... The vaccine in low doses was deemed safe and effective in order to advance a phase III clinical trial using two 100-μg doses ...
... and the protocol has not been shown to be effective in clinical trials. Despite the lack of clinical efficacy, the protocol has ... Guaifenesin protocol is an unapproved treatment for fibromyalgia suggested in the 1990s by R. Paul St. Amand. The protocol ... He has recommended a follow-up study be conducted which controls for all elements of the protocol. The lead author of the study ... Amand, who participated as a "Study Advisor" to this clinical trial, has stated that the study did not control for salicylate ...
"ABM Clinical Protocol #26: Persistent Pain with Breastfeeding". Breastfeeding Medicine. 11 (2): 46-53. doi:10.1089/bfm. ... Kulkarni, Dhananjay (2020). "Clinical Presentations of Breast Disorders in Pregnancy and Lactation". Diseases of the Breast ... Berens, Pamela D. (December 2015). "Breast Pain: Engorgement, Nipple Pain, and Mastitis". Clinical Obstetrics & Gynecology. 58 ... "Practice-based interpretation of ultrasound studies leads the way to more effective clinical support and less pharmaceutical ...
The clinical protocol began on May 22, 1989, and included 10 patients. The procedure was shown to be safe. Rosenberg went on to ... Only after approval by that formal public governmental review did the gene therapy clinical protocol move on for review by the ... Microinjecting a few non-stem cells was clearly not an efficient procedure for a clinical protocol. In 1984, Anderson published ... Anderson, together with bioethicist John Fletcher, set the ethical standard for this type of clinical protocol in his 1980 ...
Hippocrates introduced the first healthcare system based on science and clinical protocols. Hippocrates' theories about physics ... "Clinical pharmacology in the Middle Ages: Principles that presage the 21st century". Clinical Pharmacology & Therapeutics. 67 ( ... and the introduction of clinical pharmacology. Institutionalization of medicine was another important achievement in the ...
He improved and standardized clinical protocols for conducting Laryngeal electromyography in patients. He established clinical ... Later he moved to Norway, where he did a specialization degree in clinical neurophysiology at Oslo University in 1970. He then ... Kotby, M. Nasser (2018-12-28). "Egypt: Four Decades of Voice Research and Clinical Application". The ASHA Leader. 11 (7): 30-32 ... Kotby, M. Nasser; Haugen, L. K. (1970). "Clinical Application of Electromyography in Vocal Fold Mobility Disorders". Acta Oto- ...
Bagatto, M; Moodie, S; Scollie, S; Seewald, R; Moodie, S; Pumford, J; Liu, KP (2005). "Clinical protocols for hearing ... As with most clinical tests, standardized calibration of the test environment, the equipment and the stimuli is needed before ... Although pure-tone audiometry has many clinical benefits, it is not perfect at identifying all losses, such as 'dead regions' ... Handbook of clinical audiology. Katz, Jack., Burkard, Robert, 1953-, Medwetsky, Larry. (5th ed.). Philadelphia: Lippincott ...
Typical stimulation protocols used in clinical FES involves trains of electric pulses. Biphasic, charged balanced pulses are ... Initial Phase II clinical trials conducted with FEST for reaching and grasping, and walking were carried out at KITE, the ... Taylor PN, Burridge JH, Dunkerley AL, Wood DE, Norton JA, Singleton C, Swain ID (1999). "Clinical use of the Odstock dropped ... initial clinical results" (PDF). Artificial Organs. 26 (3): 267-270. doi:10.1046/j.1525-1594.2002.06949.x. PMID 11940030.{{cite ...
"Clinical Management Protocol for Covid-19 (in Adults)" (PDF). Ministry of Health and Family Welfare. 24 May 2021. "Health ... ministry issues revised clinical management protocols for Covid-19 amid spurt in cases". Times of India. Press Trust of India. ... Plasma or serum concentrations are usually in a range of 0.1-1.6 mg/L during therapy and 6-20 mg/L in cases of clinical ... "No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19". Recovery Trial, Nuffield Department ...

No FAQ available that match "clinical protocols"

No images available that match "clinical protocols"